B-intervention	0	14	Bisphosphonate
I-intervention	15	26	risedronate
O	27	35	prevents
B-condition	36	40	bone
I-condition	41	45	loss
O	46	48	in
B-eligibility	49	54	women
I-eligibility	55	59	with
I-eligibility	60	70	artificial
I-eligibility	71	80	menopause
I-eligibility	81	84	due
I-eligibility	85	87	to
I-eligibility	88	100	chemotherapy
I-eligibility	101	103	of
I-eligibility	104	110	breast
I-eligibility	111	117	cancer
O	117	118	:
O	119	120	a
O	121	127	double
O	127	128	-
O	128	133	blind
O	133	134	,
O	135	142	placebo
O	142	143	-
O	143	153	controlled
O	154	159	study
O	159	160	.

O	161	163	To
O	164	173	determine
O	174	177	the
O	178	191	effectiveness
O	192	195	and
O	196	202	safety
O	203	205	of
O	206	209	the
O	210	224	bisphosphonate
O	225	236	risedronate
O	237	239	in
O	240	250	preventing
O	251	255	bone
O	256	260	loss
O	261	263	in
O	264	269	young
O	270	275	women
O	276	280	with
O	281	287	breast
O	288	294	cancer
O	295	298	and
O	299	304	early
O	305	314	menopause
O	315	322	induced
O	323	325	by
O	326	338	chemotherapy
O	339	342	who
O	343	346	are
O	347	349	at
O	350	355	major
O	356	360	risk
O	361	364	for
O	365	368	the
O	369	380	development
O	381	383	of
O	384	398	postmenopausal
O	399	411	osteoporosis
O	411	412	.

B-total-participants	413	418	Fifty
I-total-participants	418	419	-
I-total-participants	419	424	three
B-ethinicity	425	430	white
O	431	436	women
O	436	437	,
O	438	442	aged
B-age	443	445	36
I-age	446	448	to
I-age	449	451	55
I-age	452	457	years
O	457	458	,
O	459	463	with
O	464	470	breast
O	471	477	cancer
O	478	481	and
O	482	494	artificially
O	495	502	induced
O	503	512	menopause
O	513	517	were
O	518	528	stratified
O	529	538	according
O	539	541	to
O	542	547	prior
O	548	557	tamoxifen
O	558	561	use
O	561	562	.

O	563	569	Thirty
O	569	570	-
O	570	573	six
O	574	582	patients
O	583	591	received
O	592	601	tamoxifen
O	602	603	(
O	603	605	20
O	606	608	mg
O	608	609	/
O	609	610	d
O	610	611	)
O	611	612	.

O	613	619	Within
O	620	624	each
O	625	632	stratum
O	632	633	,
O	634	642	patients
O	643	647	were
O	648	656	randomly
O	657	665	assigned
O	666	668	to
O	669	676	receive
O	677	688	risedronate
O	689	690	(
O	690	691	n
O	692	693	=
B-intervention-participants	694	696	27
O	696	697	)
O	698	700	or
B-control	701	708	placebo
O	709	710	(
O	710	711	n
O	712	713	=
B-control-participants	714	716	26
O	716	717	)
O	717	718	.

O	719	728	Treatment
O	729	738	consisted
O	739	741	of
O	742	747	eight
O	748	754	cycles
O	755	759	oral
O	760	771	risedronate
O	772	774	30
O	775	777	mg
O	777	778	/
O	778	779	d
O	780	782	or
O	783	790	placebo
O	791	796	daily
O	797	800	for
O	801	802	2
O	803	808	weeks
O	809	817	followed
O	818	820	by
O	821	823	10
O	824	829	weeks
O	830	832	of
O	833	835	no
O	836	840	drug
O	841	842	(
O	842	844	12
O	845	850	weeks
O	851	854	per
O	855	860	cycle
O	860	861	)
O	861	862	.

O	863	871	Patients
O	872	876	were
O	877	886	monitored
O	887	890	for
O	891	892	a
O	893	898	third
O	899	903	year
O	904	911	without
O	912	921	treatment
O	921	922	.

O	923	927	Main
O	928	936	outcomes
O	937	939	of
O	940	943	the
O	944	949	study
O	950	954	were
B-outcome-Measure	955	962	changes
I-outcome-Measure	963	965	in
I-outcome-Measure	966	972	lumbar
I-outcome-Measure	973	978	spine
I-outcome-Measure	979	982	and
I-outcome-Measure	983	991	proximal
I-outcome-Measure	992	997	femur
O	998	999	(
O	999	1006	femoral
O	1007	1011	neck
O	1011	1012	,
O	1013	1023	trochanter
O	1023	1024	,
O	1025	1028	and
O	1029	1033	Ward
O	1033	1034	'
O	1034	1035	s
O	1036	1044	triangle
O	1044	1045	)
B-outcome-Measure	1046	1050	bone
I-outcome-Measure	1051	1058	mineral
I-outcome-Measure	1059	1066	density
I-outcome-Measure	1067	1068	(
I-outcome-Measure	1068	1071	BMD
I-outcome-Measure	1071	1072	)
O	1072	1073	,
O	1074	1077	and
B-outcome-Measure	1078	1089	biochemical
I-outcome-Measure	1090	1097	markers
I-outcome-Measure	1098	1100	of
I-outcome-Measure	1101	1105	bone
I-outcome-Measure	1106	1114	turnover
O	1114	1115	.

O	1116	1118	In
O	1119	1127	contrast
O	1128	1130	to
O	1131	1132	a
O	1133	1144	significant
O	1145	1153	decrease
O	1154	1156	of
B-outcome	1157	1160	BMD
I-outcome	1161	1163	at
I-outcome	1164	1167	the
I-outcome	1168	1174	lumbar
I-outcome	1175	1180	spine
I-outcome	1181	1184	and
I-outcome	1185	1188	hip
O	1189	1191	in
O	1192	1195	the
O	1196	1203	placebo
O	1204	1209	group
O	1209	1210	,
O	1211	1216	there
O	1217	1220	was
O	1221	1223	an
O	1224	1232	increase
O	1233	1235	in
B-outcome	1236	1239	BMD
O	1240	1242	in
O	1243	1246	the
O	1247	1258	risedronate
O	1259	1264	group
O	1264	1265	.

O	1266	1268	On
O	1269	1278	treatment
O	1279	1289	withdrawal
O	1289	1290	,
B-outcome	1291	1295	bone
I-outcome	1296	1300	loss
O	1301	1307	ensued
O	1307	1308	,
O	1309	1314	which
O	1315	1323	suggests
O	1324	1328	that
O	1329	1338	treatment
O	1339	1344	needs
O	1345	1347	to
O	1348	1350	be
O	1351	1361	continuous
O	1362	1364	to
O	1365	1373	maintain
O	1374	1375	a
O	1376	1386	protective
O	1387	1393	effect
O	1394	1396	on
O	1397	1401	bone
O	1402	1406	mass
O	1406	1407	.

O	1408	1410	At
O	1411	1412	2
O	1413	1418	years
O	1418	1419	,
O	1420	1423	the
O	1424	1428	mean
O	1429	1439	difference
O	1440	1441	(
O	1441	1442	+
O	1442	1443	/
O	1443	1444	-
O	1445	1448	SEM
O	1448	1449	)
O	1450	1457	between
O	1458	1464	groups
O	1465	1468	was
O	1469	1470	2
O	1470	1471	.
O	1471	1472	5
O	1472	1473	%
O	1474	1475	+
O	1475	1476	/
O	1476	1477	-
O	1478	1479	1
O	1479	1480	.
O	1480	1481	2
O	1481	1482	%
O	1482	1483	,
O	1484	1485	(
O	1485	1487	95
O	1487	1488	%
O	1489	1499	confidence
O	1500	1508	interval
O	1509	1510	[
O	1510	1512	CI
O	1512	1513	]
O	1513	1514	,
O	1515	1516	0
O	1516	1517	.
O	1517	1518	2
O	1519	1521	to
O	1522	1523	4
O	1523	1524	.
O	1524	1525	9
O	1525	1526	)
O	1527	1529	at
O	1530	1533	the
O	1534	1540	lumbar
O	1541	1546	spine
O	1547	1548	(
O	1548	1549	P
O	1550	1551	=
O	1552	1553	.
O	1553	1556	041
O	1556	1557	)
O	1558	1561	and
O	1562	1563	2
O	1563	1564	.
O	1564	1565	6
O	1565	1566	%
O	1567	1568	+
O	1568	1569	/
O	1569	1570	-
O	1571	1572	1
O	1572	1573	.
O	1573	1574	1
O	1574	1575	%
O	1575	1576	,
O	1577	1578	(
O	1578	1580	95
O	1580	1581	%
O	1582	1584	CI
O	1584	1585	,
O	1586	1587	0
O	1587	1588	.
O	1588	1589	3
O	1590	1592	to
O	1593	1594	4
O	1594	1595	.
O	1595	1596	8
O	1596	1597	)
B-outcome	1598	1600	at
I-outcome	1601	1604	the
I-outcome	1605	1612	femoral
I-outcome	1613	1617	neck
O	1618	1619	(
O	1619	1620	P
O	1621	1622	=
O	1623	1624	.
O	1624	1627	029
O	1627	1628	)
O	1628	1629	.

O	1630	1637	Similar
O	1638	1645	results
O	1646	1650	were
O	1651	1659	observed
B-outcome	1660	1662	at
I-outcome	1663	1666	the
I-outcome	1667	1670	hip
I-outcome	1671	1681	trochanter
O	1681	1682	.

O	1683	1690	Results
O	1691	1693	by
O	1694	1701	stratum
O	1702	1710	indicate
O	1711	1712	a
O	1713	1723	beneficial
O	1723	1724	,
O	1725	1733	although
O	1734	1741	partial
O	1741	1742	,
O	1743	1749	effect
O	1750	1752	of
O	1753	1762	tamoxifen
O	1763	1765	in
O	1766	1774	reducing
O	1775	1779	bone
O	1780	1784	loss
O	1784	1785	.

O	1786	1797	Risedronate
O	1798	1801	was
B-outcome	1802	1806	well
I-outcome	1807	1816	tolerated
O	1817	1820	and
O	1821	1827	showed
O	1828	1829	a
O	1830	1834	good
B-outcome	1835	1841	safety
I-outcome	1842	1849	profile
O	1849	1850	,
O	1851	1855	with
O	1856	1858	no
O	1859	1867	evidence
O	1868	1870	of
B-outcome	1871	1881	laboratory
I-outcome	1882	1895	abnormalities
O	1895	1896	.

O	1897	1908	Risedronate
O	1909	1916	appears
O	1917	1919	to
O	1920	1922	be
O	1923	1924	a
O	1925	1929	safe
O	1930	1939	treatment
O	1940	1944	that
O	1945	1953	prevents
O	1954	1958	both
O	1959	1969	trabecular
O	1970	1973	and
O	1974	1982	cortical
O	1983	1987	bone
O	1988	1992	loss
O	1993	1995	in
O	1996	2001	women
O	2002	2006	with
O	2007	2016	menopause
O	2017	2024	induced
O	2025	2027	by
O	2028	2040	chemotherapy
O	2041	2044	for
O	2045	2051	breast
O	2052	2058	cancer
O	2058	2059	.
